ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
TORONTO and HAIFA, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic…
Orion and Aiforia extend collaboration to preclinical study evaluations
March 05, 2025 02:00 ET | Source: Orion Oyj ORION CORPORATION PRESS…
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritisPivotal clinical trial…
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody,…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc.…
Derm-Biomes DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc,…
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
February 23, 2025 12:07 ET | Source: IO Biotech • Findings support…
BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion
- Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named…
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share…